Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy

Human Pathology

Volumn 27, Issue 7, 1996, Pages 683-687

  Weinstein, Michael H ^b   Partin, Alan W ^b   Veltri, Robert W ^b   Epstein, Jonathan I ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

chromogranin; neuroendocrine; progression; prostate; radical prostatectomy

Indexed keywords

CHROMOGRANIN A;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PROSTATE ADENOCARCINOMA; TUMOR DIFFERENTIATION;

EID: 0030015190     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90398-6     Document Type: Article

References (16)

1. Cohen RJ, Glezerson G, Haffejee Z, et al: Prostatic carcinoma: Histological and immunohistological factors affecting prognosis. Br J Urol 66:405-410, 1990
2. Cohen RJ, Glezerson G, Haffejee Z, et al: Neuro-endocrine cells: A new prognostic parameter in prostate cancer. Br J Urol 68:258-262, 1991
3. Wright C, Grignon D, Shum D, et al: Neuroendocrine differentiation in prostatic adenocarcinoma is not an independent prognostic indicator. Mod Pathol 5:61A, 1992 (abstr)
4. Grignon D, Caplan R, Sakr W, et al: Neuroendocrine (NE) differentiation as a prognostic indicator in locally advanced prostate cancer (PCa): A study based on RTOG protocol 8610. Mod Pathol 8:76A, 1995 (abstr)
5. Noordzij MA, van der Kwast TH, van Steenbrugge GJ, et al: The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 62:252-258, 1995
6. Abrahamsson PA, Wadstrom LB: Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 182:298-307, 1987
7. Abrahamsson PA, Falkmer S, Falt K, et al: The course of neuroendocrine differentiation in prostatic carcinomas. Pathol Res Pract 185:373-380, 1989
8. Cohen MK, Arber DA, Coffield KS, et al: Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 74:1899-1903, 1994
9. Bonkhoff H, Wernert N, Dhom G, et al: Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 19:91-98, 1991
10. Capella C, Usellini L, Buffa R, et al: The endocrine component of prostatic carcinomas, mixed adenocarcinoma-carcinoid tumours and non-tumour prostate: Histochemical and ultrastructural identification of the endocrine cells. Histopathology 5:175-192, 1981
11. di Sant'Agnese PA, de Mesy Jensen KL, Churukian CJ, et al: Human prostatic endocrine-paracrine (APUD) cells. Arch Pathol Lab Med 109:607-612, 1985
12. di Sant'Agnese PA, de Mesy Jensen KL: Neuroendocrine differentiation in prostatic carcinoma. HUM PATHOL 18:849-856, 1987
13. Bostwick DG, Dousa MK, Crawford BG, et al: Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol 18:1240-1246, 1994
14. Aprikian AG, Cordon-Cardo C, Fair WR, et al: Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71:3952-3965, 1993
15. Aprikian AG, Cordon-Cardo C, Fair WR, et al: Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol 151:914-919, 1994
16. Kadmon D, Thompson TC, Lynch GR, et al: Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 146:358-361, 1991